GuidelineAmerican journal of clinical pathology2017
Molecular Biomarkers for the Evaluation of Colorectal Cancer.
Guideline in American journal of clinical pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The role of health economic evidence in clinical practice guidelines for colorectal cancer: a comparative analysis across countries.Journal of comparative effectiveness research · 2025Pooled it
- The Heterogeneity of Mucinous Colorectal Adenocarcinoma-Histologic and Molecular Phenotypes Drive Prognostic Outcomes.Cancers · 2026Article
- High Glycolysis and Lipid Metabolism Status Predicts Poor Prognosis in Colorectal Cancer Patients.Current molecular medicine · 2026Article
- Mapping Manual Laboratory Tasks to Robot Movements in Digital Pathology Workflow.Sensors (Basel, Switzerland) · 2025Article
- Deficient DNA mismatch repair and Nectin-4 expression in upper tract urothelial carcinoma (UTUC).Journal of cancer research and clinical oncology · 2025Article
- Harnessing immunotherapy in sporadic MSI-H/dMMR colorectal cancer: a case study.Journal of surgical case reports · 2025Article
- A Systematic Review of Disappearing Colorectal Liver Metastases: Resection or No Resection?Journal of clinical medicine · 2025Review
- Machine learning-based radiomics approach assessing preoperative non-contrast CT for microsatellite instability prediction in colon cancer.Frontiers in physiology · 2025Article
- What are the experiences of colorectal cancer patients with biomarker testing in Canada?: a mixed methods study.BMC cancer · 2024Article
- Effect of genetic profiling on surgical decisions at hereditary colorectal cancer syndromes.Heliyon · 2024Review
- Early evaluation of the effectiveness and cost-effectiveness of ctDNA-guided selection for adjuvant chemotherapy in stage II colon cancer.Therapeutic advances in medical oncology · 2024Article
- A picture is worth a thousand words: advancing the use of visualization tools in implementation science through process mapping and matrix heat mapping.Implementation science communications · 2023Article
- The Clinical Significance of Septin 9 and Colon Cancer Specific Antigen-2 (CCSA-2) in Colorectal Cancer.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Microsatellite instability assessment is instrumental for Predictive, Preventive and Personalised Medicine: status quo and outlook.The EPMA journal · 2023Review
- Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohort.Journal of clinical pathology · 2023Article
- Heme Metabolism-Related Gene TENT5C is a Prognostic Marker and Investigating Its Immunological Role in Colon Cancer.Pharmacogenomics and personalized medicine · 2023Article
- Article
- Measuring and Improving Quality of Colonoscopy for Colorectal Cancer Screening.Techniques and innovations in gastrointestinal endoscopy · 2022Article
- Resource Oriented Decision Making for Treatment of Metastatic Colorectal Cancer (mCRC) in a Lower-Middle Income Country: Egyptian Foundation of Medical Sciences (EFMS) Consensus Recommendations 2020.Cancer management and research · 2022Article
- Colorectal cancers with a residual adenoma component: Clinicopathologic features and KRAS mutation.PloS one · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
Objectives: To develop evidence-based guideline recommendations through a systematic review of the literature to establish standard molecular biomarker testing of colorectal cancer (CRC) tissues to guide epidermal growth factor receptor (EGFR) therapies and conventional chemotherapy regimens. Methods: The American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology convened an expert panel to develop an evidence-based guideline to establish standard molecular biomarker testing and guide therapies for patients with CRC. A comprehensive literature search that included more than 4,000 articles was conducted. Results: Twenty-one guideline statements were established. Conclusions: Evidence supports mutational testing for EGFR signaling pathway genes, since they provide clinically actionable information as negative predictors of benefit to anti-EGFR monoclonal antibody therapies for targeted therapy of CRC. Mutations in several of the biomarkers have clear prognostic value. Laboratory approaches to operationalize CRC molecular testing are presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.